All News
Efficacy of Subsequent b/tsDMARD Use in Rheumatoid Arthritis
Analysis of rheumatoid arthritis (RA) data from the British Society for Rheumatology Biologics Register shows that, even after failing three or more biologic or targeted synthetic DMARDs (b/tsDMARDs), patients may continue to benefit from repeated trials of unused b/tsDMARDs.
Read ArticleRheumNow Podcast – What You Do For & What You Do To the Patient (4.8.2022)
Dr. Jack Cush reviews the news and journal articles from the past week and discusses the use of fibroscan in RA, steroid hip injections in OA and famous quotes from a famous cardiologist.
Read Article
Links:
Tocilizumab Works Best in Non-Mechanical Ventilated COVID-19 Patients
JAMA has published a meta-analysis of 15 studies of hospitalized patients with COVID-19 treated with tocilizumab and corticosteroids, showing that a clinically meaningful mortality benefit from tocilizumab (and steroids) was best seen in those not requiring invasive mechanical ventilation (IMV).
Read ArticleACR Updates Clinical Guidance for Multisystem Inflammatory Syndrome in Children Associated With COVID
A Task Force from the ACR has provided an updated (version 3) guidance for the diagnosis and management of Multisystem Inflammatory Syndrome in Children (MIS-C), a COVID related condition characterized by fever, inflammation, and multiorgan dysfunction.
Read Article

Links:


Links:
Dr. John Cush RheumNow ( View Tweet)
2021 Rheumatology Year in Review
Our top 10 list of advances, game-changers, worries and those better medical practices that evolved during 2021.
Read ArticleClinical Practice Guidelines for Multisystem Inflammatory Syndrome in Children
Multisystem inflammatory syndrome in children (MIS-C) is new and serious complication of COVID-19 that preferentially affects adolescents. A review of proposed management guidelines is compiled in this report, suggesting a unified approach to therapeutic management of MIS-C.
Read Article
Links:
Serious Adverse Events Associated with Tocilizumab in COVID-19 Patients
Safety analysis of over 1000 adverse events associated with the use of tocilizumab in the treatment of COVID‐19 infection shows both rare expected and some unexpected AE.
Read ArticleWhen to Stop Biologics in Systemic JIA?
Systemic onset juvenile idiopathic arthritis (sJIA) is a dramatic onset inflammatory condition marked by spiking fevers, intermittent rash, polyarthritis and a host of other hyperinflammatory manifestations.
Read ArticleCytokine Inhibitor Lung Disease in Still's Linked to HLA-DRB1 Alleles
Pulmonary complications in the setting of Still's disease (juvenile and adult) has seldom but consistently been reported, including reports of pneumonitis, pulmonary hypertension and a severe or fatal lung disease, often associated with hypersensitivity to anticytokine therapy. A multicenter study reports that drug hypersensitivity and pulmonary reactions in Still's patients receiving IL-1 or IL-6 inhibitors is strongly associated with HLA-DRB1*15 haplotypes.
Read ArticleThe Influence of Obesity on Choice of Biologic in Rheumatoid Arthritis
In rheumatoid arthritis we have a wide range of options available to us when we progress to a biologic treatment option. We have little to differentiate between these agents based on the clinical trials.
Read ArticleTop vasculitis takeaways from ACR 2021
There were several hot topics at ACR21. Here I concentrate on top abstracts in vasculitis.
Read Article

